A study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid plus tacrolimus in idiopathic membranous nephropathy

A study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid Plus tacrolimus in idiopathic membranous nephropathy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16008344

Enrollment

Unknown

Registered

2016-04-22

Start date

2016-04-19

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic membranous nephropathy

Interventions

A:cyclophosphamide

B:tacrolimus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Clinical pathology diagnosis of membranous nephropathy and all patients were screened for secondary membranous nephropathy; 2. 24 hour urine protein greater than 6g, or even from 3.5g to 6g, but nephrotic syndrome is obvious; 3. Normal serum creatinine; 4. Voluntary and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Secondary membranous nephropathy; 2. Patients with serious complications, malignancy, pregnant,severe liver damage and other drug contraindications; 3. Patients who rejected this regimen or could not follow up were excluded; 4. Treatment with glucocorticoid or other immunosuppressive agents within 1 month before enrollment; 5. Known allergy to the calcineurin inhibitors.

Design outcomes

Primary

Measure	Time frame
24h-UP;Alb;Scr;Adverse event rate;	—

Countries

China

Contacts

Public ContactWei Su

Baoji Central Hospital

suwei831@foxmail.com+86 13992778118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026